January 7, 2020

First U.S. Clinical Use of Next-Generation Device Brings New Light to Brain Resections

Cleveland Clinic surgeons remove first brain tumor with Myriad NOVUS tool

glioma resection using Myriad NOVUS

In early December 2019, a Cleveland Clinic surgical team ushered in an era of enhanced visualization during subcortical brain tumor resection with the first U.S. clinical use of the recently approved NICO Myriad NOVUS resection tool.


Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

The next-generation NICO Myriad, which won FDA clearance in September 2019, provides an enhancement to improve the efficiency of the Myriad resection tool’s suction capability and comes with the new Myriad-LX xenon light source at the tip of the device to illuminate the surgical field for enhanced visualization of tissue.

“The new device offers enhanced, variable suction and cutting along with the addition of the xenon light, which provides much better visualization without need for a microscope or external lighting,” says Alireza Mohammadi, MD, the neurosurgeon with Cleveland Clinic’s Rose Ella Burkhardt Brain Tumor and Neuro-Oncology Center who performed the initial U.S. resection with the tool.

The successful procedure was performed in a glioma patient undergoing awake surgery (see intraoperative photo above), although the device can be used for resection of all brain tumor types.


“We believe the enhanced visualization of the surgical field made possible by the built-in light will translate to safer and more efficacious tumor resection and shorter operative times,” says Dr. Mohammadi. “The improved visualization should be particularly helpful for resection of deep-seated tumors.”

Because Dr. Mohammadi was experienced in the use of the first-generation Myriad tool, he needed no additional training to adopt the new device, which he says will replace the prior version at Cleveland Clinic. He and his colleagues plan to use the new device in an upcoming clinical trial.

Like its predecessor version, the Myriad NOVUS tool is approved for neurosurgical indications including removal of primary and secondary brain tumors, vascular abnormalities and malformations, and intraventricular tumors and cysts. Neurosurgeons in Cleveland Clinic’s Cerebrovascular Center are adopting it for use as well.


Related Articles

Physician with patient
February 21, 2024
Strategies for Improving Clinical Trial Equity

Cleveland Clinic Cancer Institute takes multi-faceted approach to increasing clinical trial access

How antibody drug conjugates work
February 13, 2024
Real-World Use of Trastuzumab Deruxtecan

Key learnings from DESTINY trials

February 7, 2024
Advances in Bone Marrow Transplant Have Improved Outcomes in Fanconi Anemia

Overall survival in patients treated since 2008 is nearly 20% higher than in earlier patients

February 5, 2024
Haploidentical Bone Marrow Transplant Has Durable Engraftment in Patients With Sickle Cell Disease

Two-year event-free survival comparable to matched sibling donor myeloablative transplant

February 1, 2024
Possibilities of CRISPR Technology (Podcast)

Gene editing technology offers promise for treating multiple myeloma and other hematologic malignancies, as well as solid tumors

January 30, 2024
Gene Therapy Trials Show Positive Results in Sickle Cell Disease and Thalassemia

First-in-human trials of CRISPR-Cas12a gene editing demonstrate safety and meaningful event-free survival

photo of Elekta Esprit Gamma Knife machine
January 26, 2024
The Evolution of Gamma Knife Technology (Podcast)

Improvements enable targeting of brain tumors with single-session, fractionated or neoadjuvant approaches

Disparities in multiple myeloma
January 25, 2024
Major Study Identifies Global Disparities in Drug Toxicity for Multiple Myeloma Treatment

Study of 401,576 patients reveals differences in cancer burdens as well as overall survival